Osamu Yoshida, MD, Ph D, President and CEO of iPS Academia Japan, stated, "Dr. Yamanaka's goal is to see the application of iPSC technology utilized broadly to benefit the health and well-being of people. Toward this end, iPS Academia Japan is pleased to partner with Cellular Dynamics, the leader in iPSC-derived tissue manufacturing, thereby making the benefits of this technology widely available to researchers in Japan through our distribution and support of CDI's iCell products."
Robert Palay, CEO and chairman of the board of CDI, noted, "We are pleased that iPS Academia Japan, of which Dr. Yamanaka is a member of their scientific advisory board, chose to distribute CDI's iPSC-derived iCell products. This new distribution agreement, along with our prior licensing agreement, sets the stage for a strong partnership that will foster collaboration to move our technology forward."
Chris Parker, VP and Chief Commercial Officer of CDI, said, "CDI has made great strides in industrializing the process of manufacturing iPSCs and terminal cell types in the quantity, quality, and purity required for the pharmaceutical industry. We are pleased to partner with a distributor in Japan who shares our vision of delivering high quality iPSC-derived cellular tools to researchers. This partnership puts CDI one step closer to making our cellular research tools available worldwide."
About Cellular Dynamics International
Cellular Dynamics International, Inc. (CDI) is a leading developer
|SOURCE Cellular Dynamics International|
Copyright©2010 PR Newswire.
All rights reserved